A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Conditions:   Sickle Cell Disease;   Hematological Diseases;   Hemoglobinopathies Intervention:   Biological: CTX001 Sponsors:   CRISPR Therapeutics;   Vertex Pharmaceuticals Incorporated Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials